Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals, a member of the Fresenius Kabi Group of companies, is set to market breast cancer drug Letrozole Tablets in the US, following the US Food and Drug Administration's (FDA) approval.
Subscribe to our email newsletter
Letrozole Tablets, USP is an aromatase inhibitor indicated as an adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Letrozole Tablets, which are therapeutically equivalent to the Novartis Pharmaceuticals’ Femara, will be marketed in 2.5g strength.
APP Pharma president and CEO John Ducker said the approval of Letrozole further expands the company’s oncology product portfolio in this strategically prominent market segment.